Long-Term Safety and Efficacy of SPK-8011 in Males With Hemophilia A
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Anemia, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/19/2018 |
| Start Date: | August 14, 2018 |
| End Date: | December 2022 |
A Multi-Center Evaluation of the Long-Term Safety and Efficacy of SPK-8011 [Adeno-Associated Viral Vector With B-Domain Deleted Human Factor VIII Gene] in Males With Hemophilia A
This long-term follow-up study will continue to evaluate the long-term safety and efficacy of
SPK-8011 in males with hemophilia A, who have received a single intravenous administration of
SPK-8011 in any Spark-sponsored SPK-8011 study.
SPK-8011 in males with hemophilia A, who have received a single intravenous administration of
SPK-8011 in any Spark-sponsored SPK-8011 study.
This study will follow patients with hemophilia A, who have received a single intravenous
administration of SPK-8011 in any prior Spark-sponsored SPK-8011 study. Subjects will be
followed for up to a total of 5 years post infusion (including the time on the dosing study).
administration of SPK-8011 in any prior Spark-sponsored SPK-8011 study. Subjects will be
followed for up to a total of 5 years post infusion (including the time on the dosing study).
Inclusion Criteria:
1. Males with hemophilia A, who have received a single intravenous administration of
SPK-8011 in any Spark sponsored SPK-8011 study
2. Individuals who understand the purpose and the risks of the study, and who provide
signed and dated informed consent before undergoing any study-specific procedures.
Exclusion Criteria:
1. Individuals who are unable or unwilling to comply with the schedule of visits and study
assessments as described in this study protocol.
We found this trial at
2
sites
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
Click here to add this to my saved trials